PARP inhibitor attenuated colony formation can be restored by MAP kinase inhibitors in different irradiated cancer cell lines

References

• Abd Elmageed ZY, Naura AS, Errami Y, Zerfaoui M. 2012. The poly(ADP-ribose) polymerases (PARPs): New roles in intracellular transport. Cell Signal 24:1–8.
   PubMed Web of Science ®Google Scholar
• Affolter A, Fruth K, Brochhausen C, Schmidtmann I, Mann WJ, Brieger J. 2010. Activation of mitogen-activated protein kinase extracellular signal-related kinase in head and neck squamous cell carcinomas after irradiation as part of a rescue mechanism. Head Neck 33:1448–57.
   PubMedGoogle Scholar
• Alexy T, Toth A, Marton Z, Horvath B, Koltai K, Feher G, Kesmarky G, Kalai T, Hideg K, Sumegi B, et al. 2004. Inhibition of ADP-evoked platelet aggregation by selected poly(ADP-ribose) polymerase inhibitors. J Cardiovasc Pharmacol 43:423–431.
   PubMedGoogle Scholar
• Arai K, Lee SR, van Leyen K, Kurose H, Lo EH. 2004. Involvement of ERK MAP kinase in endoplasmic reticulum stress in SH-SY5Y human neuroblastoma cells. J Neurochem 89:232–9.
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, et al. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 376:245–251.
   PubMed Web of Science ®Google Scholar
• Brown JM, Attardi LD. 2005. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5:231–237.
   PubMed Web of Science ®Google Scholar
• Catz SD, Johnson JL. 2003. BCL-2 in prostate cancer: A mini review. Apoptosis 8:29–37.
   PubMed Web of Science ®Google Scholar
• Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle DA, Boddy AV, et al. 2010. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. Br J Cancer 103:1588–1596.
   PubMed Web of Science ®Google Scholar
• Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay A, Lord CJ, et al. 2010. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2:53ra75.
   Google Scholar
• Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, et al. 2011. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 103:334–346.
   PubMed Web of Science ®Google Scholar
• Erster S, Moll UM. 2004. Stress-induced p53 runs a direct mitochondrial death program: Its role in physiologic and pathophysiologic stress responses in vivo. Cell Cycle 3:1492–1495.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Morselli E, Kepp O, Tajeddine N, Kroemer G. 2008. Targeting p53 to mitochondria for cancer therapy. Cell Cycle 7: 1949–1955.
   PubMed Web of Science ®Google Scholar
• Gangopadhyay NN, Luketich JD, Opest A, Visus C, Meyer EM, Landreneau R, Schuchert MJ. 2011. Inhibition of poly(ADP-ribose) polymerase (PARP) induces apoptosis in lung cancer cell lines. Cancer Invest 29:608–616.
   PubMed Web of Science ®Google Scholar
• Gao L, Feng Y, Bowers R, Becker-Hapak M, Gardner J, Council L, Linette G, Zhao H, Cornelius LA. 2006. Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: Two processes important to melanoma tumorigenesis and metastasis. Cancer Res 66:7880–7888.
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, et al. 2011. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12:852–861.
   PubMed Web of Science ®Google Scholar
• Geng L, Huehls AM, Wagner JM, Huntoon CJ, Karnitz LM. 2011. Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil. PLoS One 6:e28862.
   Google Scholar
• Hagan MP, Yacoub A, Dent P. 2007. Radiation-induced PARP activation is enhanced through EGFR-ERK signaling. J Cell Biochem 101: 1384–1393.
   PubMedGoogle Scholar
• Issaeva N, Thomas HD, Djureinovic T, Jaspers JE, Stoimenov I, Kyle S, Pedley N, Gottipati P, Zur R, Sleeth K, et al. 2010. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res 70:6268–6276.
   PubMedGoogle Scholar
• Kalai T, Balog M, Szabo A, Gulyas G, Jeko J, Sumegi B, Hideg K. 2009. New poly(ADP-ribose) polymerase-1 inhibitors with antioxidant activity based on 4-carboxamidobenzimidazole-2-ylpyrroline and -tetrahydropyridine nitroxides and their precursors. J Med Chem 52:1619–1629.
   PubMed Web of Science ®Google Scholar
• Khalil A, Morgan RN, Adams BR, Golding SE, Dever SM, Rosenberg E, Povirk LF, Valerie K. 2011. ATM-dependent ERK signaling via AKT in response to DNA double-strand breaks. Cell Cycle 10:481–491.
   PubMed Web of Science ®Google Scholar
• Kim DS, Kim SY, Lee JE, Kwon SB, Joo YH, Youn SW, Park KC. 2003. Sphingosine-1-phosphate-induced ERK activation protects human melanocytes from UVB-induced apoptosis. Arch Pharm Res 26: 739–746.
   PubMedGoogle Scholar
• Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA. 2010. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28:3555–3561.
   PubMed Web of Science ®Google Scholar
• Kovacs K, Toth A, Deres P, Kalai T, Hideg K, Gallyas F Jr, Sumegi B. 2006. Critical role of PI3-kinase/Akt activation in the PARP inhibitor induced heart function recovery during ischemia-reperfusion. Biochem Pharmacol 71:441–452.
   PubMedGoogle Scholar
• Kovacs K, Hanto K, Bognar Z, Tapodi A, Bognar E, Kiss GN, Szabo A, Rappai G, Kiss T, Sumegi B, et al. 2009. Prevalent role of Akt and ERK activation in cardioprotective effect of Ca(2+) channel- and beta-adrenergic receptor blockers. Mol Cell Biochem 321:155–164.
   PubMedGoogle Scholar
• Lee KB, Kim KR, Huh TL, Lee YM. 2008a. Proton induces apoptosis of hypoxic tumor cells by the p53-dependent and p38/JNK MAPK signaling pathways. Int J Oncol 33:1247–1256.
   PubMedGoogle Scholar
• Lee KB, Lee JS, Park JW, Huh TL, Lee YM. 2008b. Low energy proton beam induces tumor cell apoptosis through reactive oxygen species and activation of caspases. Exp Mol Med 40:118–129.
   PubMed Web of Science ®Google Scholar
• Lu K, Liang CL, Liliang PC, Yang CH, Cho CL, Weng HC, Tsai YD, Wang KW, Chen HJ. 2010. Inhibition of extracellular signal- regulated kinases 1/2 provides neuroprotection in spinal cord ischemia/reperfusion injury in rats: Relationship with the nuclear factor-kappaB-regulated anti-apoptotic mechanisms. J Neurochem 114:237–246.
   PubMedGoogle Scholar
• Ma ZC, Hong Q, Wang YG, Tan HL, Xiao CR, Liang QD, Wang DG, Gao Y. 2011. Ferulic acid protects lymphocytes from radiation-predisposed oxidative stress through extracellular regulated kinase. Int J Radiat Biol 87:130–140.
   PubMed Web of Science ®Google Scholar
• Marampon F, Gravina GL, Di Rocco A, Bonfili P, Di Staso M, Fardella C, Polidoro L, Ciccarelli C, Festuccia C, Popov VM, et al. 2011. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. Mol Cancer Ther 10:159–168.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Basecke J, et al. 2011. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol 226:2762–2781.
   PubMed Web of Science ®Google Scholar
• Mester L, Szabo A, Atlasz T, Szabadfi K, Reglodi D, Kiss P, Racz B, Tamas A, Gallyas F Jr, Sumegi B, et al. 2009. Protection against chronic hypoperfusion-induced retinal neurodegeneration by PARP inhibition via activation of PI-3-kinase Akt pathway and suppression of JNK and p38 MAP kinases. Neurotox Res 16:68–76.
   PubMedGoogle Scholar
• Oliver FJ, Menissier-de Murcia J, Nacci C, Decker P, Andriantsitohaina R, Muller S, de la Rubia G, Stoclet JC, de Murcia G. 1999. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 18:4446–4454.
   PubMed Web of Science ®Google Scholar
• Rios J, Puhalla S. 2011. PARP inhibitors in breast cancer: BRCA and beyond. Oncology (Williston Park) 25:1014–1025.
   PubMed Web of Science ®Google Scholar
• Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O’Connor MJ, Wedge SR, Stratford IJ. 2011. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther 10:1949–1958.
   PubMed Web of Science ®Google Scholar
• Sun Y, Moretti L, Giacalone NJ, Schleicher S, Speirs CK, Carbone DP, Lu B. 2011. Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models. J Thorac Oncol 6:699–706.
   Google Scholar
• Tang Y, Wang YL, Yang L, Xu JX, Xiong W, Xiao M, Li M. 2013. Inhibition of arginine ADP-ribosyltransferase 1 reduces the expression of poly(ADP-ribose) polymerase-1 in colon carcinoma. Int J Mol Med 32:130–136.
   PubMed Web of Science ®Google Scholar
• Tomiyama A, Tachibana K, Suzuki K, Seino S, Sunayama J, Matsuda KI, Sato A, Matsumoto Y, Nomiya T, Nemoto K, et al. 2010. MEK- ERK-dependent multiple caspase activation by mitochondrial proapoptotic Bcl-2 family proteins is essential for heavy ion irradiation-induced glioma cell death. Cell Death Dis 1:e60.
   PubMed Web of Science ®Google Scholar
• Toshimitsu H, Yoshimoto Y, Augustine CK, Padussis JC, Yoo JS, Angelica Selim M, Pruitt SK, Friedman HS, Ali-Osman F, Tyler DS. 2010. Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma. Ann Surg Oncol 17:2247–2254.
   PubMed Web of Science ®Google Scholar
• Veres B, Radnai B, Gallyas F, Jr., Varbiro G, Berente Z, Osz E, Sumegi B. 2004. Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice. J Pharmacol Exp Ther 310:247–255.
   PubMed Web of Science ®Google Scholar
• Wang L, Mason KA, Ang KK, Buchholz T, Valdecanas D, Mathur A, Buser-Doepner C, Toniatti C, Milas L. 2011. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs 30:2113–20.
   Google Scholar
• Xiao H, Zhang Q, Shen J, Bindokas V, Xing HR. 2010. Pharmacologic inactivation of kinase suppressor of Ras1 sensitizes epidermal growth factor receptor and oncogenic Ras-dependent tumors to ionizing radiation treatment. Mol Cancer Ther 9:2724–2736.
   PubMedGoogle Scholar
• Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR. 2011. Novel targeted therapeutics: Inhibitors of MDM2, ALK and PARP. J Hematol Oncol 4:16.
   PubMed Web of Science ®Google Scholar
• Zerfaoui M, Errami Y, Naura AS, Suzuki Y, Kim H, Ju J, Liu T, Hans CP, Kim JG, Abd Elmageed ZY, et al. 2010. Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-kappa B upon TLR4 stimulation. J Immunol 185:1894–1902.
   PubMed Web of Science ®Google Scholar
• Zhao X, Ning Q, Sun X, Tian D. 2011. Pokemon reduces Bcl-2 expression through NF-kappa Bp65: A possible mechanism of hepatocellular carcinoma. Asian Pac J Trop Med 4:492–497.
   PubMedGoogle Scholar